Key Developments: PerkinElmer Inc (PKI)
32.54USD
21 May 2013
$0.31 (+0.96%)
$32.19
$32.25
$32.62
$32.21
1,041,283
1,209,442
$35.86
$23.73
Latest Key Developments (Source: Significant Developments)
PerkinElmer Inc Lowers FY 2013 Guidance
PerkinElmer Inc updated its fiscal 2013 guidance and expects organic revenue to increase in the low-single digit range relative to fiscal 2012 and GAAP earnings per share (EPS)from continuing operations in the range of $1.30 to $1.40 and on a non-GAAP basis, which is expected to include the adjustments noted in the attached reconciliation, adjusted earnings per share in the range of $2.00 to $2.10. The Company reported revenues of $2.14 billion in fiscal 2012. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $2.24 billion and EPS of $2.29 for fiscal 2013. Full Article
PerkinElmer Inc Issues FY 2013 Guidance In Line With Analysts' Estimates
PerkinElmer Inc announced that for fiscal 2013, it expects organic revenue to increase in the mid-single digit range relative to fiscal 2012, GAAP earnings per share from continuing operations in the range of $1.57-$1.65 and adjusted earnings per share to $2.24-$2.32. The Company reported revenues of $2.14 billion in fiscal 2012. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $2.24 billion and EPS of $2.32 for fiscal 2013. Full Article
PerkinElmer Inc Declares Quarterly Dividend
PerkinElmer Inc announced that it has declared a regular quarterly dividend of $0.07 per share of common stock on January 25, 2013. This dividend is payable on May 10, 2013, to all shareholders of record at the close of business on April 19, 2013. Full Article
PerkinElmer Inc And Verinata Health, Inc Announces Collaboration
PerkinElmer Inc and Verinata Health, Inc., announced a strategic agreement for expanding access to Verinata's verifi test, the comprehensive non-invasive prenatal test (NIPT) currently available for high-risk pregnancies. The verifi test, which is performed at Verinata's CLIA-certified, California laboratory, uses a single maternal blood draw as early as 10 weeks of pregnancy to detect multiple fetal chromosomal aneuploidies. Chromosomal aneuploidy is an abnormal number of chromosomes. Under the terms of the collaboration agreement, PerkinElmer will serve as an exclusive Verinata Health commercial partner in the joint sales and marketing of the verifi test in the United States. The collaboration consolidates and streamlines delivery of prenatal testing options due to the combination of PerkinElmer's prenatal testing menu with Verinata's technologies for the early, non-invasive identification of specific fetal chromosomal aneuploidies. Full Article
PerkinElmer Inc Reaffirms FY 2012 Revenue Guidance; Raises FY 2012 EPS Guidance
PerkinElmer Inc announced that for fiscal 2012, it expects organic revenue to increase in the mid-single digit range relative to fiscal 2011, GAAP earnings per share from continuing operations in the range of $1.22-$1.24 and adjusted earnings per share to $2.05-$2.07. The Company reported revenues of $1.95 billion in fiscal 2011. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $2.12 billion and EPS of $2.05 for fiscal 2012. Full Article
PerkinElmer Inc Declares Quarterly Dividend
PerkinElmer Inc announced that the Board of Directors declared a regular quarterly dividend of $0.07 per share of common stock on October 24, 2012. This dividend is payable on February 8, 2013, to all shareholders of record at the close of business on January 18, 2013. Full Article
PerkinElmer Inc Updates FY 2012 Revenue Guidance-Conference Call
PerkinElmer Inc announced that for fiscal 2012, it expects revenue to be about $2.2 billion. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $2.12 for fiscal 2012. Full Article
PerkinElmer Inc Reaffirms FY 2012 Guidance
PerkinElmer Inc announced that for fiscal 2012, it has reiterated forecast for organic revenue to increase in the mid-single digit range relative to fiscal 2011 and GAAP earnings per share from continuing operations in the range of $1.21 to $1.26 and reaffirms its previously communicated guidance for adjusted earnings per share, which is expected to include the adjustments noted in the attached reconciliation, of $2.00 to $2.05. The Company reported revenues of $1.95 billion in fiscal 2011. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenues of $2.157 billion and EPS of $2.04 for fiscal 2012. Full Article
PerkinElmer Inc Declares Quarterly Dividend
PerkinElmer Inc announced that it has declared a regular quarterly dividend of $0.07 per share of common stock on July 27, 2012. This dividend is payable on November 9, 2012, to all shareholders of record at the close of business on October 19, 2012. Full Article
PerkinElmer Inc Declares Quarterly Dividend
PerkinElmer Inc announced that its Board of Directors declared a regular quarterly dividend of $0.07 per share of common stock on June 15, 2012. This dividend is payable on August 10, 2012, to all shareholders of record at the close of business on July 20, 2012. Full Article
PerkinElmer profit misses expectations, lowers forecast
- PerkinElmer Inc on Thursday reported lower-than-expected first-quarter profit and decreased its full-year forecast as difficult economic conditions and a stronger dollar hurt sales in Europe and Japan.
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
